Safety Alerts & Recalls

What does this mean?

Although the results from the SEAS study raise concerns about a possible link between Vytorin and cancer, several other larger ongoing trials do not show an increased risk of cancer with Vytorin. The FDA expects to release a final review about the safety of Vytorin in about 9 months. Based on the currently available information, the FDA has determined that patients should continue to take Vytorin or any other cholesterol-lowering drug.

FDA Is Reviewing Results From a Recent Clinical Trial of Vytorin

The FDA announced that it is reviewing the results of the "SEAS" trial - a clinical study that raised concerns about the risk of cancer in patients taking Vytorin compared with those given a placebo. Vytorin is a combination of two medications, simvastatin (Zocor) and ezetimibe (Zetia) and is used to lower cholesterol.

For more information please visit: more information here

Source: FDA
Publication Date: 2008-08-22
Last Updated: 2009-12-05

Visit the medication page for the following drugs:

Share your story Share your story! Tell us how MediGuard has helped you or someone you love. Mobile graphic Download the MediGuard Mobile App to manage your prescription and over-the-counter medications, for free. Registration Info Taking multiple medications puts you at risk for possible drug-drug interactions Registration Info Monitor the medical treatment of you and your loved ones.